Integrated DNA Technologies (IDT) has launched the Alt-R HDR Enhancer Protein, a newly developed solution designed to facilitate an up to two-fold increase in HDR efficiency in challenging cells, including iPSCs and HSPCs.
This new, proprietary molecule expands IDT’s portfolio of HDR reagents to empower cell and gene therapy developers with an accelerated path for their therapeutic research programs. Manufactured by Aldevron, Alt-R HDR Enhancer Protein maintains cell viability and genomic integrity, with no increase in off-target edits or translocations.
While CRISPR-Cas systems are highly efficient at generating knockouts through NHEJ, knock-in via HDR remains a challenge in primary and difficult-to-edit cells. Various studies performed using IDT’s Alt-R HDR Enhancer Protein indicate a significant boost in HDR efficiency across multiple loci and cell types, highlighting the effectiveness of the novel, protein-based solution for basic research and translational applications. The findings also revealed that the Alt-R HDR Enhancer Protein preserves editing specificity and is well-suited for high-fidelity editing workflows.
The Alt-R HDR Enhancer Protein is available in RUO format at 500 μg and 5 mg with CGMP grade to follow. The enhancer protein seamlessly integrates into existing workflows, and is compatible with different Cas systems and common delivery methods.
